The Risk-Benefit Paradigm vs the Causal Exposure Paradigm: LDL as a primary cause of vascular disease

Journal of Clinical Lipidology

Volumn 8, Issue 6, 2014, Pages 594-605

  Toth, Peter P ^a,b   Thanassoulis, George ^c   Williams, Ken ^d   Furberg, Curt D ^e   Sniderman, Allan ^c  

^a CGH MEDICAL CENTER   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c ROYAL VICTORIA HOSPITAL   (Canada)

^d UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^e WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

Atherosclerosis; Cardiovascular risk; Causal exposure paradigm; Cholesterol; Guideline; Risk benefit paradigm

Indexed keywords

BIOLOGICAL MARKER; CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ARTERY WALL; ARTICLE; ATHEROSCLEROSIS; BLOOD PRESSURE; CARDIOVASCULAR RISK; CAUSAL ATTRIBUTION; CLINICAL TRIAL (TOPIC); CORONARY ARTERY ATHEROSCLEROSIS; HUMAN; LIPOPROTEIN BLOOD LEVEL; PRACTICE GUIDELINE; PRIMARY PREVENTION; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; VASCULAR DISEASE; WEAKNESS; ARTERY; BLOOD; CARDIOVASCULAR DISEASES; COMPLICATION; DRUG EFFECTS; EVIDENCE BASED MEDICINE; HYPERTENSION; MEDICAL SOCIETY; PATHOLOGY; PATIENT SELECTION; RISK ASSESSMENT; UNITED STATES;

AMERICAN HEART ASSOCIATION; ARTERIES; CARDIOVASCULAR DISEASES; CAUSALITY; CHOLESTEROL, LDL; EVIDENCE-BASED MEDICINE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERTENSION; PATIENT SELECTION; PRACTICE GUIDELINES AS TOPIC; RISK ASSESSMENT; UNITED STATES;

EID: 84928821623     PISSN: 19332874     EISSN: 18764789     Source Type: Journal    
DOI: 10.1016/j.jacl.2014.08.004     Document Type: Article

References (54)

1. N.J. Stone, J. Robinson, A.H. Lichtenstein, and et al. 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines Circulation 2013 Nov 12 [Epub ahead of print]
2. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III) JAMA 285 2001 2486 2497
3. Z. Reiner, A.L. Catapano, G. De Backer, and et al. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS) Eur Heart J 32 2011 1769 1818
4. J. Genest, R. McPherson, J. Frohlich, and et al. 2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult - 2009 recommendations Can J Cardiol 25 2009 567 579
5. Expert Dyslipidemia Panel of the International Atherosclerosis Society Panel members An International Atherosclerosis Society Position Paper J Clin Lipidol 8 2014 29 60
6. JBS3 Board Joint British Societies' consensus recommendations for the prevention of cardiovascular disease (JBS3) Heart 100 Suppl 2 2014 ii1 ii67
7. Heart Protection Study Collaborative Group MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo controlled trial Lancet 360 2002 7 22
8. Cholesterol Treatment Trialists (CTT) C. Baigent, L. Blackwell, J. Emberson, and et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials Lancet 376 2010 1670 1681
9. V. Fuster, L. Badimon, J.J. Badimon, and J.H. Chesebro The pathogenesis of coronary artery disease and the acute coronary syndromes N Engl J Med 326 1992 242 250
10. M.C.A. Kramer, S.Z.H. Rittersma, R.J. de Winter, and et al. Relationship of thrombus healing to underlying plaque morphology in sudden coronary death J Am Coll Cardiol 55 2010 122 132
11. F.D. Kolodgie, H.K. Gold, A.P. Burke, and et al. Intraplaque hemorrhage and progression of coronary atheroma N Engl J Med 349 2003 2316 2325
12. J.C. Cohen, E. Boerwinkle, T.H. Mosley Jr., and H.H. Hobbs Sequence variations in PCSK9, low LDL, and protection against coronary heart disease N Engl J Med 354 2006 1264 1272
13. B.A. Ference, W. Yoo, I. Alesh, and et al. Effect of long-term exposure to lower low-density lipoprotein cholesterol beginning early in life on the risk of coronary heart disease: a Mendelian randomization analysis J Am Coll Cardiol 60 2012 2631 2639
14. S. Shah, J.P. Casas, F. Drenos, and et al. Causal relevance of blood lipid fractions in the development of carotid atherosclerosis: Mendelian randomization analysis Circ Cardiovasc Genet 6 2013 63 72
15. M.V. Holmes, F.W. Asselbergs, T.M. Palmer, and et al. Mendelian randomization of blood lipids for coronary heart disease Eur Heart J 2014 Jan 27 [Epub ahead of print]
16. A.M. Noyes, and P.D. Thompson A systematic review of the time course of atherosclerotic plaque regression Atherosclerosis 234 2014 75 84
17. M.J. Pencina, A.M. Navar-Boggan, R.B. D'Agostino Sr., and et al. Application of new cholesterol guidelines to a population-based sample N Engl J Med 370 2014 1422 1431
18. A.D. Sniderman, P. Toth, G. Thanassoulis, M. Pencina, and C. Furberg Taking a longer term view of cardiovascular risk: the causal exposure paradigm Br Med J 348 2014 g3047
19. G. Sangiorgi, J.A. Rumberger, A. Severson, and et al. Arterial calcification and not lumen stenosis is highly correlated with atherosclerotic plaque burden in humans: a histologic study of 723 coronary artery segments using nondecalcifying methodology J Am Coll Cardiol 31 1998 126 133
20. J. Shemesh Detection and quantification of coronary calcium with dual-slice CT U. Joseph Schoepf, Contemporary Cardiology: CT of the Heart: Principles and Applications. Chapter 10 Calcium Detection with Dual-Slice CT 2005 Humana Press, Inc. Totowa, NJ 91 99
21. A.D. Sniderman, G. Thanassoulis, P.R. Lawler, K. Williams, and C.D. Furberg Comparison of coronary calcium screening versus broad statin therapy for patients at intermediate cardiovascular risk Am J Cardiol 110 2012 530 533
22. M.J. Pletcher, M. Pignone, S. Earnshaw, and et al. Using the coronary artery calcium score to guide statin therapy: a cost-effectiveness analysis Circ Cardiovasc Qual Outcomes 7 2014 276 284
23. A. Landry, J.D. Spence, and A. Fenster Measurement of carotid plaque volume by 3-dimensional ultrasound Stroke 35 2004 864 869
24. W.C. Cromwell, J.D. Otvos, M.J. Keyes, and et al. LDL Particle Number and Risk of Future Cardiovascular Disease in the Framingham Offspring Study - Implications for LDL Management J Clin Lipidol 1 2007 583 592
25. J.D. Otvos, S. Mora, I. Shalaurova, and et al. Clinical implications of discordance between low-density lipoprotein cholesterol and particle number J Clin Lipidol 5 2011 105 113
26. A.D. Sniderman, S. Islam, S. Yusuf, and M.J. McQueen Discordance analysis of apolipoprotein B and non-high density lipoprotein cholesterol as markers of cardiovascular risk in the INTERHEART study Atherosclerosis 225 2012 444 449
27. S. Mora, J.E. Buring, and P.M. Ridker Discordance of low-density lipoprotein (LDL) cholesterol with alternative LDL-related measures and future coronary events Circulation 129 2014 553 561
28. J.H. Contois, G.R. Warnick, and A.D. Sniderman Reliability of low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B measurement J Clin Lipidol 5 2011 264 272
29. J.C. LaRosa, S.M. Grundy, D.D. Waters, and et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease N Engl J Med 352 2005 1425 1435
30. P.M. Ridker, E. Danielson, F.A. Fonseca, and et al. Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial Lancet 373 2009 1175 1182
31. http://wwwn.cdc.gov/nchs/nhanes/search/datapage.aspx?Component=Laboratory&CycleBeginYear=2005hdl-d.htm (Atch 1) & tchol-d.htm (Atch 2). Accessed May 6, 2014.
32. R.R. Giraldez, R.P. Giugliano, S. Mohanavelu, and et al. Baseline low-density lipoprotein cholesterol is an important predictor of the benefit of intensive lipid-lowering therapy: a PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) analysis J Am Coll Cardiol 52 2008 914 920
33. M.A. Pfeffer, F.M. Sacks, L.A. Moye, and et al. Influence of baseline lipids on effectiveness of pravastatin in the CARE Trial. Cholesterol And Recurrent Events J Am Coll Cardiol 33 1999 125 130
34. S.M. Boekholdt, B.J. Arsenault, S. Mora, and et al. Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysis JAMA 307 2012 1302 1309
35. S. Mora, N.K. Wenger, D.A. DeMicco, and et al. Determinants of residual risk insecondary prevention patients treated with high- versus low-dose statin therapy: the Treating to New Targets (TNT) Study Circulation 125 2012 1979 1987
36. S. Mora, R.J. Glynn, S.M. Boekholdt, B.G. Nordestgaard, J.J. Kastelein, and P.M. Ridker On-treatment nonhigh-density ipoprotein cholesterol, apolipoprotein B, triglycerides, and lipid ratios in relation to residual vascular risk after treatment with potent statin therapy J Am Coll Cardiol 59 2012 1521 1528
37. B.C. Fellstrom, A.G. Jardine, R.E. Schmieder, and et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis N Engl J Med 360 2009 1395 1407
38. C. Wanner, V. Krane, W. Marz, and et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis N Engl J Med 353 2005 238 248
39. J. Kjekshus, E. Apetrei, V. Barrios, and et al. Rosuvastatin in Older Patients with Systolic Heart Failure N Engl J Med 357 2007 2248 2261
40. F.M. Sacks, M.A. Pfeffer, L.A. Moye, and et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators N Engl J Med 335 1996 1001 1009
41. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group N Engl J Med 339 1998 1349 1357
42. F.M. Sacks, A.M. Tonkin, J. Shepherd, and et al. Effect of Pravastatin on Coronary Disease Events in Subgroups Defined by Coronary Risk Factors: The Prospective Pravastatin Pooling Project Circulation 102 2000 1893 1900
43. M.R. Law, N.J. Wald, and A.R. Rudnicka Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis BMJ 326 2003 1423
44. H. Soran, J.D. Schofield, and P.N. Durrington The importance of considering LDL cholesterol response as well as cardiovascular risk in deciding who can benefit from statin therapy Curr Opin Lipidol 25 2014 239 246
45. Heart Protection Study Collaborative Group R. Bulbulia, L. Bowman, K. Wallendszus, and et al. Effects on 11-year mortality and morbidity of lowering LDL cholesterol with simvastatin for about 5 years in 20,536 high-risk individuals: a randomised controlled trial Lancet 378 2011 2013 2020
46. J.R. Downs, M. Clearfield, S. Weis, and et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study JAMA 279 1998 1615 1622
47. H. Nakamura, K. Arakawa, H. Itakura, et al. MEGA Study Group Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial Lancet 368 9542 2006 1155 1163
48. D.P. Mikhailidis, and A.S. Wierzbicki The GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study Curr Med Res Opin 18 2002 215 219
49. C.P. Cannon, E. Braunwald, C.H. McCabe, and et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes N Engl J Med 350 2004 1495 1504
50. G.L. Knatterud, Y. Rosenberg, L. Campeau, and et al. Long-term effects on clinical outcomes of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation in the post coronary artery bypass graft trial. Post CABG Investigators Circulation 102 2000 157 165
51. T. Pedersen, O. Faergeman, J. Kastelein, and et al. High-dose atorvastatin versus usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial JAMA 294 2005 2437 2445
52. Study of the Effectiveness of Additional Reductions in C, Homocysteine Collaborative Group J. Armitage, L. Bowman, K. Wallendszus, and et al. Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12,064 survivors of myocardial infarction: a double-blind randomised trial Lancet 376 2010 1658 1669
53. A. Sniderman, G. Thanassoulis, P. Couture, K. Williams, A. Alam, and C.D. Furberg Is lower and lower better and better? A re-evaluation of the evidence from the Cholesterol Treatment Trialists' Collaboration meta-analysis for low-density lipoprotein lowering J Clin Lipidol 6 2012 303 309
54. A.D. Sniderman, K.J. LaChapelle, N.A. Rachon, and C.D. Furberg The necessity for clinical reasoning in the era of evidence-based medicine Mayo Clin Proc 88 2013 1108 1114